Overview

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is: - To evaluate whether 7-day treatment with oral QLT091001 can improve visual function in RP subjects with an autosomal dominant mutation in RPE65. - To evaluate duration of visual function improvement (if observed) in RP subjects with an autosomal dominant mutation in RPE65 after 7-day treatment with oral QLT091001. - To evaluate the safety of oral QLT091001 administered once daily for 7 days in RP subjects with an autosomal dominant mutation in RPE65.

Phase:

Phase 1

Details

Lead Sponsor:

QLT Inc.

Treatments:

Retinol acetate
Vitamin A